Share This Article:

Canine Cutaneous Mast Cell Tumor: Biologic Behavior and Its Correlation with Prognostic Indicators

Full-Text HTML XML Download Download as PDF (Size:153KB) PP. 255-261
DOI: 10.4236/ojvm.2012.24041    4,585 Downloads   8,428 Views   Citations

ABSTRACT

Cutaneous mast cell tumor (MCT) shows a variable biological behavior in dogs and may present either as solitary masse that can be treated and cured with surgical removal or as a systemic metastatic and fatal disease. Histological grade, KIT pattern and proliferative index are typically prognostic factors in MCTs. In the present study, we have investigated correlation between clinical data (breed, age, gender, tumour location, tumor size, time before surgery, number of tumours, occurrence of metastasis and recurrence), cellular proliferation (Ki-67, mitotic index), intratumoural microvessel density (IMVD) and apoptotic index with the histological grade and KIT pattern. 28 tumors, from 20 dogs with cutaneous MCT were evaluated. There was association between histological grade, IMVD, tumor ulceration and number of tumors. A significant increase of Ki-67 expression and mitotic index was observed in MCTs with cytoplasmic KIT staining pattern. Patnaik histological grade system was related to mitotic index. Histological grade in canine cutaneous MCT should not be assessed as the only prognostic factor, but associated with KIT pattern, IMDV, cellular proliferation, presence of tumour ulceration, number of tumours, recurrences and metastases.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

S. dos Santos Costa Poggiani, E. Maria Terra, R. Torres Neto, M. Tinucci Costa and R. Laufer Amorim, "Canine Cutaneous Mast Cell Tumor: Biologic Behavior and Its Correlation with Prognostic Indicators," Open Journal of Veterinary Medicine, Vol. 2 No. 4, 2012, pp. 255-261. doi: 10.4236/ojvm.2012.24041.

References

[1] J. A. Villamil, C. J. Henry, J. N. Bryan, M. Ellersieck, L. Schultz, J. W. Tyler and A. W. Hahn, “Identification of the Most Common Cutaneous Neoplasms in Dogs and Evaluation of Breed and Age Distributions for Selected Neoplasms,” Journal of the American Veterinary Medical Association, Vol. 239, No. 7, 2011, pp. 960-965. doi:10.2460/javma.239.7.960
[2] J. D. Webster, V. Yuzbasiyan-Gurkan, D. H. Thamm, E. Hamilton and M. Kiupel, “Evaluation of Prognostic Markers for Canine Mast Cell Tumors Treated with Vinblastine and Prednisone,” BMC Veterinary Research, Vol. 4, 2008, p. 32. doi:10.1186/1746-6148-4-32
[3] J. D. Webster, M. Kiupel, J. B. Kaneene, R. Miller and V. Yuzbasiyan-Gurkan, “The Use of KIT and Tryptase Expression Patterns as Prognostic Tools for Canine Cutaneous Mast Cell Tumors,” Veterinary Pathology, Vol. 41, No. 3, 2004, pp. 371-377. doi:10.1354/vp.41-4-371
[4] M. Kiupel, J. D. Webster, R. A. Miller and J. B. Kaneene, “Impact of Tumour Depth, Tumour Location and Multiple Synchronous Masses on the Prognosis of Canine Cutaneous Mast Cell Tumours,” Journal of Veterinary Medicine. Series A, Physiology, Pathology, Clinical Medicine, Vol. 52, No. 6, 2005, pp. 280-286. doi:10.1111/j.1439-0442.2005.00726.x
[5] T. J. Scase, D. Edwards, J. Miller, W. Henley, K. Smith, A. Blunden and S. Murphy, “Canine Mast Cell Tumors: Correlation of Apoptosis and Proliferation Markers with Prognosis,” Journal of Veterinary Internal Medicine, Vol. 20, No. 1, 2006, pp. 151-158. doi:10.1111/j.1939-1676.2006.tb02835.x
[6] E. M. Romansik, C. M. Reilly, P. H. Kass, P. F. Moore and P. F. London, “Mitotic Index Is Predictive for Survival for Canine Cutaneous Mast Cell Tumors,” Veterinary Pathology, Vol. 44, No. 3, 2007, pp. 335-341. doi:10.1354/vp.44-3-335
[7] S. J. Withrow and D. M. Vail, “Small Animal Clinical Oncology,” 4th Edition, WB Saunders, Philadelphia, 2007.
[8] D. J. Argyle, M. M. Turek and M. J. Brearley, “Decision Making in Small Animal Oncology,” Blackwell, Singapore, 2008.
[9] R. L. Amorim, “Biomarcadores Prognósticos em Mastocitomas Cutaneos Caninos, Avalia??o em Laminas de Arranjo de Matriz Tecidual (TMA),” Thesis, Universidade Estadual Paulista, Botucatu, 2011.
[10] N. C. northrup, E. W. Howerth, B. G. Harmon, C. A. Brown, K. P. Carmicheal, A. P. Garcia, K. S. Latimer, J. S. Munday, P. M. Rakich, L. J. Richey, N. L. Steadman and T. L. Gieger, “Variation among Pathologists in the Histologic Grading of Canine Cutaneous Mast Cell Tumors with Uniform Use of a Single Grading Reference,” Journal of Veterinary Diagnostic Investigation, Vol. 17, No. 6, 2005, pp. 561-564.
[11] P. Pinczowski, R. Torres-Neto, V. E. Fabris and R. L. Amorim, “Mastocitoma Cutaneo Canino: Varia??o da Graduacao Histopatológica Entre Patologistas,” Clínica Veterinária, Vol. 77, 2008, pp. 76-78.
[12] J. J. Abadie, M. A. Amardeilh and M. E. Delverdier, “Immunohistochemical Detection of Proliferating Cell Nuclear Antigen and Ki-67 in Mast Cell Tumors from Dogs,” Journal of the American Veterinary Medical Association, Vol. 215, No. 11, 1999, pp. 1629-1634.
[13] J. D. Webster, V. Yuzbasiyan-Gurkan, D. H. Thamm, E. Hamilton and M. Kiupel, “Evaluation of Prognostic Markers for Canine Mast Cell Tumors Treated with Vinblastine and Prednisone,” BMC Veterinary Research, Vol. 4, 2008, p. 32. doi:10.1186/1746-6148-4-32
[14] J. D. Webster, V. Yuzbasiyan-Gurkan, R. A. Miller, J. B. Kaneene and M. Kiupel, “Cellular Proliferation in Canine Cutaneous Mast Cell Tumors: Associations with c-KIT and Its Role in Prognostication,” Veterinary Pathology, Vol. 44, No. 3, 2007, pp. 298-308. doi:10.1354/vp.44-3-298
[15] M. G. Alexandrakis, F. H. Passam, C. Dambaki, C. A. Pappa and E. N. Stathopoulos, “The Relation between Bone Marrow Angiogenesis and the Proliferation Index Ki-67 in Multiple Myeloma,” Journal of Clinical Pathology, Vol. 57, No. 8, 2004, pp. 856-860. doi:10.1136/jcp.2003.013110
[16] B. Wolfesberger, Z. Tonar, K. Witter, A. Guija de Arespacohaga, M. Skalicky, I. Walter, J. G. Thalhammer and G. F. Egger, “Microvessel Density in Normal Lymph Nodes and Lymphomas of Dogs and Their Correlation with Vascular Endothelial Growth Factor Expression,” Research in Veterinary Science, Vol. 85, No. 1, 2008, pp. 56-61. doi:10.1016/j.rvsc.2007.07.008
[17] G. F. M. Souza, R. A. Freitas and J. L. Miranda, “Angiogênese em Carcinoma de Células Escamosa de Língua e Lábio Inferior,” Ciência Odontológica Brasileira, Vol. 10, No. 1, 2007, pp. 12-18.
[18] R. C. Rosenthal, “The Prognostic Significance of Angiogenesis in Canine Mammary Tumors,” Journal of Veterinary Internal Medicine, Vol. 14, No. 3, 2000, pp. 248-249. doi:10.1111/j.1939-1676.2000.tb01161.x
[19] P. Maiolino, S. Papparella, B. Restucci and G. De Vico, “Angiogenesis in Squamous Cell Carcinomas of Canine Skin: An Immunohistochemical and Quantitative Analysis,” Journal of Comparative Pathology, Vol. 125, No. 2-3, 2001, pp. 117-121. doi:10.1053/jcpa.2001.0485
[20] R. Preziosi, G. Sarli and M. Paltrinieri, “Prognostic Value of Tintratumoral Vessel Density in Cutaneous Mast Cell Tumours of the Dog,” Journal of Comparative Pathology, Vol. 130, No. 2-3, 2004, pp. 143-151. doi:10.1016/j.jcpa.2003.10.003
[21] S. Murphy, A. H. Sparkes, A. S. Blunden, M. J. Brearley and K. C. Smith, “Effects of Stage and Number of Tumours on Prognosis of Dogs with Cutaneous Mast Cell Tumours,” Veterinary Record, Vol. 158, No. 9, 2006, pp. 287-291. doi:10.1136/vr.158.9.287
[22] R. M. Gil da Costa, E. Matos, A. Rema, C. Lopes, M. A. Pires and F. G?rtner, “CD117 Immunoexpression in Canine Mast Cell Tumours: Correlations with Pathological Variables and Proliferation Markers,” BioMedCentral Veterinary Research, Vol. 19, No. 3, 2007, pp. 1-7.
[23] M. M. Welle, C. R. Bley, J. Howard and S. Rüfenacht, “Canine Mast Cell Tumours: A Review of the Pathogenesis, Clinical Features, Pathology and Treatment,” Veterinary Dermatology, Vol. 19, No. 6, 2008, pp. 321-339. doi:10.1111/j.1365-3164.2008.00694.x
[24] J. M. Furlani, C. R. Daleck, F. A. M. Vicenti, A. B. Nardi, G. T. Pereira, A. E. Santana, D. Eurides and L. A. F. Silva, “Mastocitoma Canino: Estudo Retrospectivo,” Ciência Animal Brasileira, Vol. 9, 2008, pp. 242-250.
[25] T. L. Gieger, A. P. Theon, J. A. Werner, M. C. McEntee, K. M. Rassnick and H. E. V. DeCock, “Biologic Behavior and Prognostic Factors for Mast Cell Tumors of the Canine Muzzle: 24 Cases (1990-2001),” Journal of Veterinary Internal Medicine, Vol. 17, No. 5, 2003, pp. 687-692. doi:10.1111/j.1939-1676.2003.tb02501.x
[26] G. Sfiligoi, K. M. Rassnick, J. M. Scarlett, N. C. Northrup and T. L. Gieger, “Outcome of Dogs with Mast Cell Tumors in the Inguinal or Perineal Region versus Other Cutaneous Locations: 124 Cases (1990-2001),” Journal of the American Veterinary Medical Association, Vol. 226, No. 8, 2005, pp. 1368-1374. doi:10.2460/javma.2005.226.1368
[27] P. Carmeliet and R. K. Jain, “Molecular Mechanisms and Clinical Applications of Angiogenesis,” Nature, Vol. 473, No. 7347, 2011, pp. 298-307.
[28] D. Ribatti and E. Crivellato, “Mast Cells, Angiogenesis and Cancer,” Advances in Experimental Medicine and Biology, Vol. 716, 2011, pp. 270-288. doi:10.1007/978-1-4419-9533-9_14
[29] M. N. Mullins, W. S. Dernell, S. J. Withrow, E. J. Ehrhart, D. H. Thamm and S. E. Lana, “Evaluation of Prognostic Factors Associated with Outcome in Dogs with Multiple Cutaneous Mast Cell Tumors Treated with Surgery with and Without Adjuvant Treatment: 54 Cases (1998-2004),” Journal of the American Veterinary Medicine Association, Vol. 228, No. 1, 2006, pp. 91-95. doi:10.2460/javma.228.1.91
[30] R. Preziosi, G. Sarli and M. Paltrinieri, “Multivariate Survival Analysis of Histological Parameters and Clinical Presentation in Canine Cutaneous Mast Cell Tumours” Veterinary Research Communications, Vol. 31, No. 3, 2007, pp. 287-296. doi:10.1007/s11259-006-3427-9
[31] S. Murphy, A. H. Sparkes, A. S. Blunden, M. J. Brearley and K. C. Smith, “Effects of Stage and Number of Tumours on Prognosis of Dogs with Cutaneous Mast Cell Tumours,” Veterinary Record, Vol. 158, No. 9, 2006, pp. 287-291. doi:10.1136/vr.158.9.287
[32] B. Seguin, M. F. Besancon, J. L. McCallan, L. L. Dewe, M. C. Tenwolde, E. K. Wong and M. S. Kent, “Recurrence Rate, Clinical Outcome, and Cellular Proliferation Indices as Prognostic Indicators after Incomplete Surgical Excision of Cutaneous Grade II Mast Cell Tumors: 28 Dogs (1994-2002),” Journal of Veterinary Internal Medicine, Vol. 20, No. 4, 2006, pp. 933-940.
[33] M. Kiupel, J. D. Webster, J. B. Kaneene, R. Miller and V. Yuzbasiyan-Gurkan, “The Use of Kit and Tryptase Expression Patterns as Prognostic Tools for Canine Cutaneous Mast Cell Tumors,” Veterinary Pathology, Vol. 41, No. 4, 2004, pp. 371-377. doi:10.1354/vp.41-4-371
[34] A. K. Patnaik, W. J. Ehler and E. G. Macewen, “Canine Cutaneous Mast Cell Tumors: Morphologic Grading and Survival Time in 83 Dogs,” Veterinary Pathology, Vol. 21, No. 5, 1984, pp. 469-474.
[35] M. Kiupel, et al., “Proposal of a Two-Tier Histologic Grading System for Canine Cutaneous Mast Cell Tumors to More Accurately Predict Biological Behavior,” Veterinary Pathology, Vol. 48, No. 1, 2011, pp. 147-155.
[36] D. Stefanello, P. Valenti, S. Faverzani, V. Bronzo, V. Fiorbianco, N. Pinto da Cunha, S. Romussi, M. Cantatore and M. Caniatti, “Ultrasound-Guided Cytology of Spleen and Liver: A Prognostic Tool in Canine Cutaneous Mast Cell Tumor,” Journal of Veterinary Internal Medicine, Vol. 23, No. 5, 2009, pp. 1051-1057. doi:10.1111/j.1939-1676.2009.0354.x
[37] A. P. Book, J. Fidel, T. Wills, J. Bryan, R. Sellon and J. Matton, “Correlation of Ultrasound Findings Liver and Spleen Cytology, and Prognosis in the Clinical Staging of High Metastatic Risk Canine Mast Cell Tumors,” Veterinary Radiology & Ultrasound, Vol. 52, No. 5, 2011, pp. 548-554. doi:10.1111/j.1740-8261.2011.01839.x

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.